The Centers for Medicare & Medicaid Services (CMS) announced that beginning July 1, 2026, eligible Medicare beneficiaries will have access to GLP-1 medications for $50 per month.
Eligible Medicare beneficiaries enrolled in Medicare Part D prescription drug plan will be able to access these medications through the Medicare GLP-1 Bridge Demonstration, which will run through December 31, 2027. The Medicare GLP-1 Bridge operates under the Secretary’s authority to test new approaches to care delivery under Medicare and is supported by CMS, including centralized processes for claims adjudication and payment to pharmacies. Part D sponsors will not bear financial risk for eligible GLP-1 drugs provided under the demonstration and will not be required to opt in for their enrollees to access these medications.
CMS will continue to work with stakeholders—including providers, pharmacies, and manufacturers—to support implementation and ensure all partners have all information prior to the demonstration’s launch.